CKD-MBD Monitoring in Maintenance Hemodialysis

Bottom Line

Part of the Maintenance Hemodialysis mastery module. This page condenses section 3 of the full white paper, Screening and Health Maintenance in Maintenance Hemodialysis, together with the mineral-metabolism rows of its quality-metrics analysis.

• The KDIGO 2017 schedule for CKD G5D: calcium and phosphorus every 1–3 months, intact PTH every 3–6 months, alkaline phosphatase every 12 months, and 25(OH) vitamin D at initiation, with repeat testing guided by the baseline value and any intervention.¹
• PTH is read as a trend, not a value. KDIGO suggests keeping PTH within approximately 2–9 times the assay's upper limit of normal (2C). Within that range a single value is unreliable for predicting bone histology, and bone biopsy, the diagnostic gold standard, is rarely performed.^1,2
• Phosphorus: lower it toward normal, without overstating the evidence. KDIGO suggests lowering elevated phosphorus toward the normal range (2C). No placebo-controlled randomized trial has shown that phosphate binders reduce mortality in dialysis.¹
• Fixing the number has not fixed the patient. In EVOLVE, cinacalcet lowered PTH but missed its composite primary end point (HR 0.93, 95% CI 0.85–1.02).³ IMPROVE-CKD, in non-dialysis CKD, found no vascular benefit from phosphate reduction.⁴
• Read phosphorus next to albumin. The phosphorus-mortality association is modified by albumin status, and phosphorus variability predicts mortality independently of the level.^5,6

1. The KDIGO 2017 Monitoring Schedule

CKD-mineral and bone disorder (CKD-MBD) monitoring on hemodialysis does two things well. It tracks the activity of the mineral disorder over time, and it exposes modifiable drivers such as vitamin D deficiency, hyperphosphatemia, inadequate dialysis, and missed medication. What the trials have not shown is that steering these values into a target range, by itself, makes patients live longer.^3,4 The schedule below should be read with both points in mind.

The KDIGO 2017 CKD-MBD guideline update sets the monitoring schedule for patients with CKD G5D, which includes everyone on maintenance hemodialysis.¹

Read the notes column as part of the schedule. KDIGO ties more frequent calcium testing to active vitamin D or calcimimetic therapy, and more frequent alkaline phosphatase testing to an elevated PTH.¹

The frequency is not settled internationally. A 2026 narrative review in BMC Nephrology compared the KDIGO, KDOQI, ERA-EDTA, and Canadian Society of Nephrology guidelines. All four agree on the core parameters, but they recommend different testing intervals and target ranges, and the authors found no true consensus on optimal frequency.⁷

2. PTH: Targets, Trends, and the Gray Zone

The target is a wide band on purpose

For patients on dialysis, KDIGO suggests maintaining PTH within approximately 2–9 times the upper limit of normal for the assay (2C).¹ That band is deliberately wide, and its anchor is assay-specific: the same absolute number can sit at a different multiple of normal depending on the laboratory. The width reflects how variable skeletal responsiveness to PTH is in ESKD. It is influenced by:

• Duration of dialysis and prior parathyroid exposure
• The degree of hyperphosphatemia and the calcium-phosphorus product
• Uremic toxin burden and chronic inflammation
• Skeletal resistance to PTH, a hallmark of uremic osteodystrophy
• Vitamin D status and therapy

Because these factors differ from patient to patient, two patients with the same PTH can have quite different bone turnover. That variability is why the band is wide, and why, within it, the direction of travel is the more useful signal.^1,2

What a single value cannot tell you

A 2023 KDIGO Controversies Conference, published in 2025, acknowledged that PTH values within this range form a gray zone in which a standalone value does not reliably predict the underlying bone histology. Bone biopsy remains the gold standard for distinguishing the subtypes of renal osteodystrophy (high-turnover, low-turnover, mixed, and osteomalacia), but it is rarely performed in clinical practice.² In most patients, management is therefore guided by biochemical trends.

Lowering PTH did not lower events: EVOLVE

EVOLVE tested whether pharmacologic PTH control improves hard outcomes on dialysis. In this randomized, placebo-controlled trial, cinacalcet lowered PTH but failed its primary composite end point of death from any cause, myocardial infarction, hospitalization for unstable angina, heart failure, or a peripheral vascular event (HR 0.93, 95% CI 0.85–1.02).³ The biology behind the PTH value was not corrected by moving the value.

That does not make PTH monitoring pointless. Trends identify patients whose mineral disorder is progressing and whose modifiable drivers need attention. What EVOLVE removes is the assumption that a lower number will, by itself, translate into fewer cardiovascular events or deaths.

3. Phosphorus: A Strong Association, a Thin Interventional Record

What the observational data show

In observational studies, hyperphosphatemia is associated with vascular calcification, cardiovascular events, and mortality, and the association is consistent across cohorts. What remains unclear is whether lowering phosphorus, particularly with binders, improves outcomes. No placebo-controlled randomized trial has shown that phosphate binder therapy reduces mortality in dialysis patients. KDIGO 2017 suggests lowering elevated phosphorus "toward the normal range" (2C) while acknowledging the limited interventional evidence.¹

The closest randomized test of the phosphate hypothesis was run outside dialysis. IMPROVE-CKD randomized patients with non-dialysis CKD to phosphate reduction and found no benefit on vascular end points.⁴ It cannot be transferred directly to hemodialysis, but it does not support the idea that binder-driven phosphorus lowering is protective.

Phosphorus cannot be read without albumin

The phosphorus-mortality relationship is not a simple line. It is modified by albumin status, and it depends on how much phosphorus moves, not only on where it sits.^5,6

The practical consequence is that the phosphorus target is not a number to hit but a pattern to stabilize, and it cannot be interpreted without knowing the albumin.^5,6 A low phosphorus is not automatically a success. In a patient whose albumin is also falling, it may mark a patient who has stopped eating.

4. Vitamin D

Vitamin D deficiency is nearly universal in ESKD. KDIGO suggests that 25(OH) vitamin D levels might be measured, with repeat testing guided by baseline values and interventions, and that deficiency be corrected using the strategies recommended for the general population (2C). Whether nutritional vitamin D supplementation with cholecalciferol or ergocalciferol improves clinical outcomes on dialysis, beyond correcting the laboratory value, remains uncertain.¹

Active vitamin D analogues (calcitriol, paricalcitol, doxercalciferol) are a different tool with a different purpose. They are used to manage secondary hyperparathyroidism, and their role in bone and cardiovascular outcomes continues to be debated. KDIGO ties more frequent calcium monitoring to their use.¹

5. The Mineral Metabolism Metrics and the Quality-Metric Trap

Every mineral metabolism value on the monthly panel follows the same pattern seen across dialysis quality metrics: a strong observational association with mortality, a guideline target, interventions deployed to hit the target, and randomized trials that do not show the target improves survival.

This is the reverse-causation trap. Sick patients have abnormal numbers, and correcting the numbers has not corrected the sickness. The same pattern for Kt/V, albumin, and hemoglobin is examined in Adequacy, nutrition, depression and cognition, and what quality metrics miss.

None of this argues for abandoning the panel. It argues for reading it as a map of disease activity and adherence rather than as a scoreboard. Monthly calcium and phosphorus, periodic PTH, and annual alkaline phosphatase still identify the patient whose mineral disorder is accelerating, whose binder or vitamin D therapy is not being taken, or whose dialysis delivery has slipped. Those are actionable findings.

6. Reading the Panel in Practice

Four habits follow from the evidence above:

1. Compare against the patient, not the target. A value that is moving deserves more attention than one that has sat at the same level for a long time.
2. Look for the modifiable driver before adding a drug. Vitamin D deficiency, hyperphosphatemia, inadequate dialysis, and medication non-adherence all push PTH upward.
3. Pair phosphorus with albumin. Low phosphorus with low albumin is a nutrition and inflammation problem, not a binder success.
4. Be honest about outcomes. No placebo-controlled trial has shown that binders reduce mortality on dialysis, and EVOLVE did not show that lowering PTH reduces events. The panel guides management; it has not been shown, by itself, to change survival.

Dialysate calcium, which also shapes the calcium balance of every treatment, is covered in Dialysate calcium, bicarbonate, magnesium, and glucose.

7. Four Patterns on the Monthly Panel

The principles above are easiest to apply as patterns. The four sketches below are illustrative teaching examples, not patients.

Pattern 1: the stable high PTH

PTH has run near 600 pg/mL for two years, and calcium and phosphorus have been steady. The trend is flat. This is a different clinical problem from a newly rising PTH, and a single value in this range does not tell you the bone histology.² Continue monitoring at the KDIGO intervals, and keep checking alkaline phosphatase, which KDIGO suggests measuring more often when PTH is elevated.¹

Pattern 2: the PTH that tripled

PTH was 200 pg/mL six months ago and is now 600 pg/mL. The number matches Pattern 1; the trajectory does not. Look for modifiable causes first: vitamin D deficiency, hyperphosphatemia, inadequate dialysis, and medication non-adherence. If the rise persists after those are addressed, escalation options are a calcimimetic, active vitamin D, or ultimately parathyroidectomy. Keep EVOLVE in mind when setting expectations: lowering PTH with cinacalcet did not reduce the composite of death and cardiovascular events.³

Pattern 3: the phosphorus that fell with the albumin

Phosphorus has drifted from high to low-normal over three months, and albumin has fallen alongside it. This is the malnutrition-inflammation phenotype, in which sick patients eat less and both values decline together, and it carries elevated mortality.⁶ It is not a binder success. Treat it as a nutrition and inflammation signal, and read the albumin with a CRP, as discussed in Adequacy, nutrition, depression and cognition, and what quality metrics miss.

Pattern 4: the phosphorus that will not settle

Phosphorus alternates between high and normal from one month to the next, and albumin is good. Two findings apply. The high-phosphorus, high-albumin pattern is the well-nourished but non-adherent phenotype, and it also carries elevated mortality.⁶ Higher variability is independently associated with worse outcomes.⁵ The goal here is a stable pattern rather than a single in-range value, which starts with a conversation about diet and medication adherence.

8. Evidence Gaps

• No placebo-controlled trial has shown that phosphate binders reduce mortality in dialysis patients. The KDIGO phosphorus recommendation is graded 2C.¹
• Optimal testing frequency is unsettled. The major international guidelines agree on what to measure but not how often.⁷
• The PTH target band is a gray zone. Standalone values within it do not reliably predict bone histology, and the diagnostic gold standard, bone biopsy, is rarely performed.²
• Nutritional vitamin D corrects the laboratory value, but its effect on clinical outcomes on dialysis is uncertain. The role of active analogues in bone and cardiovascular outcomes is still debated.¹
• Lowering PTH with cinacalcet did not reduce the composite of death and cardiovascular events in EVOLVE, and no randomized trial shows that correcting calcium reduces mortality.³

9. At the Chair

Also in this module

• Dialysate calcium, bicarbonate, magnesium, and glucose
• Cardiometabolic monitoring: lipids, statins, glycemic markers, and cardiovascular screening
• Adequacy, nutrition, depression and cognition, and what quality metrics miss
• Nutrition and protein-energy wasting on HD
• Maintenance Hemodialysis module index

Related pages

• Phosphate Management in ESRD
• Screening and Health Maintenance in Maintenance Hemodialysis, section 3 (full white paper)